Artgen Biotech PJSC engages in the discovery, research, development, and marketing of proprietary products and services in the field of regenerative medicine, medical genetics, bio-insurance, gene therapy, and biopharmaceutics. Its research and development involves gemacell and cryocell; service for personal regeneration of bone and of gum; nucleostim; preventive treatment program for primary immunodeficiency diseases; human artificial chromosome; development of drugs using histone proteins; and development of drugs using a novel technology employing polysialic acid. The company was founded by Isaev Alexandrovich Artur on November 3, 2003 and is headquartered in Moscow, Russia.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company